Increasing Incidence Rates of HIV Patients Drive the Growth of HIV-Associated Lipodystrophy Market

, the global HIV-associated lipodystrophy market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to grow at a high CAGR owing to factors like large patient pool, increasing demand for low cost drugs, rising awareness of the treatment options for HIV-associated lipodystrophy, and adoption of better healthcare facilities. North America is projected to dominate the global HIV-associated lipodystrophy market due to increasing adoption of new and technologically advanced products, high per capita health expenditure, and substantial investments in research and development for efficient treatment options.

Get accurate market forecast and analysis on the HIV-associated Lipodystrophy Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925

Key players in the global HIV-associated lipodystrophy market are Novelion Therapeutics Inc., Theratechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc (Viiv Healthcare Group of Companies), AbbVie Inc., Bristol-Myers Squibb Company, and AstraZeneca plc, among others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Company :-Transparency Market Research

User :- Aman

Email :-amanpreet@transparencymarketresearch.com

Phone :---

Mobile:- -

Url :- http://www.transparencymarketresearch.com/hiv-associated-lipodystrophy-market.html